Nuvalent, Inc. 4

Christy J. Oliger had all of her Nuvalent equity—1,324 common shares, 6,091 RSUs, and 6,119 options—cashed out or cancelled for cash at the $124.00-per-share merger price in the GSK acquisition.

On July 15, 2026, Christy J. Oliger’s Nuvalent, Inc. equity was cashed out in connection with the closing of GlaxoSmithKline’s tender offer and merger. She disposed of 1,324 shares of Class A Common Stock at $124.00 per share for approximately $164,176 in cash. In addition, 6,091 time-based restricted stock units were cancelled and converted into a cash right equal to the $124.00 offer price per underlying share (about $755,284). Separately, 6,119 stock options with a $75.53 exercise price were cancelled and converted into a cash payment equal to the intrinsic value per option (the $124.00 offer price less the $75.53 strike, or roughly $48.47 per share, for an estimated $296,946). All of these transactions were involuntary, consideration-for-merger cancellations under the Agreement and Plan of Merger, leaving Oliger with no remaining Nuvalent equity after the company became a wholly owned GSK subsidiary.

Filing Facts

CIK

1861560

Ticker

NUVL

Form

4

Source Type

fda

Accession

0001193125-26-305081

Alert Tier

6